News stories about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.1477528700927 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 26th. HC Wainwright began coverage on Axsome Therapeutics in a research report on Thursday, June 7th. They set a “buy” rating and a $10.00 price objective on the stock. ValuEngine upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, BTIG Research restated a “buy” rating and set a $16.00 price objective on shares of Axsome Therapeutics in a research report on Sunday, April 29th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.38.

NASDAQ:AXSM traded down $0.12 during trading hours on Friday, reaching $2.45. The company had a trading volume of 111,028 shares, compared to its average volume of 144,157. Axsome Therapeutics has a one year low of $2.05 and a one year high of $6.45. The company has a current ratio of 2.26, a quick ratio of 2.95 and a debt-to-equity ratio of 0.74.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.32) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.32). sell-side analysts predict that Axsome Therapeutics will post -1.08 EPS for the current year.

In related news, CFO Nick Pizzie acquired 31,000 shares of the company’s stock in a transaction on Tuesday, June 19th. The stock was purchased at an average cost of $3.10 per share, with a total value of $96,100.00. Following the acquisition, the chief financial officer now directly owns 400 shares of the company’s stock, valued at $1,240. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 34.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Recommended Story: Outstanding Shares

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.